Literature DB >> 33912819

Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation.

Luis Bahamondes1.   

Abstract

Entities:  

Year:  2021        PMID： 33912819      PMCID： PMC8066404          DOI： 10.1016/j.eclinm.2021.100857

Source DB:  PubMed          Journal:  EClinicalMedicine        ISSN： 2589-5370


× No keyword cloud information.
  10 in total

1.  Weight variation in a cohort of women using copper IUD for contraception.

Authors:  Daniela Fink Hassan; Carlos Alberto Petta; José Mendes Aldrighi; Luis Bahamondes; Marcos Perrotti
Journal:  Contraception       Date:  2003-07       Impact factor: 3.375

2.  Association of Progestin Contraceptive Implant and Weight Gain.

Authors:  Maria F Gallo; Jennifer Legardy-Williams; Tina Hylton-Kong; Carole Rattray; Athena P Kourtis; Denise J Jamieson; Markus J Steiner
Journal:  Obstet Gynecol       Date:  2016-03       Impact factor: 7.661

Review 3.  Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods.

Authors:  Luis Bahamondes; M Valeria Bahamondes; Lee P Shulman
Journal:  Hum Reprod Update       Date:  2015-06-01       Impact factor: 15.610

4.  Depo-provera associated with weight gain in Navajo women.

Authors:  E Espey; J Steinhart; T Ogburn; C Qualls
Journal:  Contraception       Date:  2000-08       Impact factor: 3.375

5.  What qualities of long-acting reversible contraception do women perceive as desirable or undesirable? A systematic review.

Authors:  Jacqueline Coombe; Melissa L Harris; Deborah Loxton
Journal:  Sex Health       Date:  2016-07-29       Impact factor: 2.706

6.  Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic.

Authors:  I Sivin; F Alvarez; D R Mishell; P Darney; L Wan; V Brache; M Lacarra; C Klaisle; J Stern
Journal:  Contraception       Date:  1998-11       Impact factor: 3.375

7.  Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.

Authors:  Waleska Modesto; Priscila de Nazaré Silva dos Santos; Vinicius Machado Correia; Luiza Borges; Luis Bahamondes
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-08-27       Impact factor: 1.848

8.  HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.

Authors: 
Journal:  Lancet       Date:  2019-06-13       Impact factor: 79.321

9.  A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.

Authors:  Luis Bahamondes; Vivian Brache; Moazzam Ali; Ndema Habib
Journal:  Contraception       Date:  2018-05-16       Impact factor: 3.375

10.  Body composition, resting energy expenditure and inflammatory markers: impact in users of depot medroxyprogesterone acetate after 12 months follow-up.

Authors:  Gisele Almeida Batista; Aglécio Luiz de Souza; Daniela Miguel Marin; Marina Sider; Vaneska Carvalho Melhado; Arlete Maria Fernandes; Sarah Monte Alegre
Journal:  Arch Endocrinol Metab       Date:  2016-09-05       Impact factor: 2.309
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.